Perrigo Company Stock (NYSE:PRGO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$27.24

52W Range

$23.89 - $34.60

50D Avg

$25.97

200D Avg

$28.32

Market Cap

$3.70B

Avg Vol (3M)

$1.44M

Beta

0.48

Div Yield

$1.10 (4.06%)

PRGO Company Profile


Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

IE

Employees

9,140

IPO Date

Dec 17, 1991

Website

PRGO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Contract Manufacturing$337.30M$350.10M$299.70M

Fiscal year ends in Dec 23 | Currency in USD

PRGO Financial Summary


Dec 23Dec 22Dec 21
Revenue$4.66B$4.45B$4.14B
Operating Income$151.90M$172.80M$573.70M
Net Income$-12.70M$-130.90M$-130.90M
EBITDA$151.90M$511.40M$885.90M
Basic EPS$-0.09$-0.97$-0.98
Diluted EPS$-0.09$-0.97$-0.98

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 06, 24 | 12:48 PM
Q2 24Aug 02, 24 | 1:18 PM
Q1 24May 07, 24 | 12:00 AM

Peer Comparison


TickerCompany
ELANElanco Animal Health Incorporated
RDYDr. Reddy's Laboratories Limited
ANIPANI Pharmaceuticals, Inc.
PAHCPhibro Animal Health Corporation
SSICSilver Spike Investment Corp.
DCPHDeciphera Pharmaceuticals, Inc.
PBHPrestige Consumer Healthcare Inc.
KMDAKamada Ltd.
PCRXPacira BioSciences, Inc.
COLLCollegium Pharmaceutical, Inc.
EGRXEagle Pharmaceuticals, Inc.
AMPHAmphastar Pharmaceuticals, Inc.